Your browser is no longer supported. Please, upgrade your browser.
AxoGen, Inc.
Index- P/E- EPS (ttm)-0.68 Insider Own2.70% Shs Outstand41.47M Perf Week-9.11%
Market Cap355.79M Forward P/E- EPS next Y-0.36 Insider Trans-3.57% Shs Float39.63M Perf Month-13.39%
Income-27.70M PEG- EPS next Q-0.13 Inst Own80.40% Short Float2.14% Perf Quarter-43.75%
Sales128.30M P/S2.77 EPS this Y19.90% Inst Trans0.30% Short Ratio2.24 Perf Half Y-58.29%
Book/sh2.78 P/B2.98 EPS next Y10.00% ROA-13.50% Target Price24.50 Perf Year-55.86%
Cash/sh2.13 P/C3.88 EPS next 5Y- ROE-23.20% 52W Range8.42 - 23.94 Perf YTD-11.63%
Dividend- P/FCF- EPS past 5Y-3.00% ROI-14.90% 52W High-65.41% Beta0.79
Dividend %- Quick Ratio5.10 Sales past 5Y32.70% Gross Margin80.00% 52W Low-1.64% ATR0.63
Employees346 Current Ratio5.80 Sales Q/Q-6.60% Oper. Margin-19.80% RSI (14)35.79 Volatility5.42% 6.43%
OptionableYes Debt/Eq0.40 EPS Q/Q-366.80% Profit Margin-21.60% Rel Volume0.77 Prev Close8.56
ShortableYes LT Debt/Eq0.40 EarningsFeb 21 AMC Payout- Avg Volume378.14K Price8.28
Recom1.90 SMA20-13.04% SMA50-16.95% SMA200-48.81% Volume290,734 Change-3.27%
Oct-23-20Initiated Guggenheim Buy $24
Jun-16-20Resumed Cantor Fitzgerald Overweight $16
May-07-20Downgrade Canaccord Genuity Buy → Hold $12
Apr-02-20Downgrade BTIG Research Buy → Neutral
Aug-07-19Downgrade William Blair Outperform → Mkt Perform
Jul-12-19Initiated Canaccord Genuity Buy $32
Mar-02-18Reiterated Lake Street Buy $26 → $38
Jan-05-18Resumed Cantor Fitzgerald Overweight
Nov-30-17Initiated Jefferies Buy $35
Nov-21-17Reiterated Lake Street Buy $22 → $26
Jul-31-17Initiated Leerink Partners Outperform $22
Jun-30-17Initiated Cantor Fitzgerald Overweight $18
Mar-06-17Initiated ROTH Capital Buy $14.50
Nov-22-16Upgrade Lake Street Hold → Buy $9 → $11
Nov-07-16Reiterated Wedbush Outperform $10 → $12
Nov-03-16Downgrade Lake Street Buy → Hold $9
Aug-04-16Reiterated Wedbush Outperform $9 → $10
May-14-14Initiated Dawson James Buy $5
Oct-31-13Reiterated Ladenburg Thalmann Buy $4.50 → $5.75
Jan-10-22 07:00AM  
Jan-04-22 07:00AM  
Dec-16-21 05:19AM  
Dec-15-21 11:39AM  
Dec-09-21 03:06PM  
Nov-10-21 07:00AM  
Nov-04-21 07:00AM  
Nov-03-21 09:31PM  
Oct-27-21 03:03PM  
Oct-17-21 08:40AM  
Oct-13-21 07:00AM  
Sep-22-21 07:00AM  
Sep-01-21 07:00AM  
Aug-18-21 06:35AM  
Aug-05-21 04:30AM  
Aug-04-21 05:55PM  
Jul-28-21 03:03PM  
Jul-22-21 07:00AM  
Jul-19-21 04:01PM  
Jul-14-21 07:00AM  
Jun-19-21 03:24AM  
May-18-21 08:43AM  
May-07-21 08:56AM  
May-06-21 07:00AM  
May-05-21 05:15PM  
Apr-28-21 12:34PM  
Apr-20-21 02:06AM  
Apr-14-21 07:00AM  
Mar-01-21 04:01PM  
Feb-22-21 04:01PM  
Feb-19-21 10:16AM  
Feb-18-21 11:47PM  
Feb-04-21 07:00AM  
Feb-01-21 07:00AM  
Jan-11-21 07:00AM  
Jan-05-21 07:00AM  
Jan-04-21 11:22PM  
Dec-23-20 07:00AM  
Dec-15-20 10:17PM  
Nov-06-20 05:38AM  
Nov-04-20 07:00AM  
Oct-30-20 02:31PM  
Oct-29-20 06:55PM  
Oct-28-20 10:15AM  
Oct-08-20 07:00AM  
Sep-30-20 04:01PM  
Sep-25-20 07:00AM  
Sep-24-20 07:00AM  
Aug-31-20 07:00AM  
Aug-07-20 09:48AM  
Aug-05-20 07:45PM  
Jul-29-20 12:33PM  
Jul-22-20 07:00AM  
Jul-15-20 07:00AM  
Jul-08-20 06:41PM  
Jul-01-20 07:00AM  
Jun-23-20 09:46AM  
Jun-01-20 07:00AM  
May-20-20 07:00AM  
May-07-20 12:00PM  
May-06-20 04:01PM  
Apr-29-20 12:34PM  
Apr-23-20 07:00AM  
Apr-15-20 07:00AM  
Apr-12-20 09:21AM  
Mar-06-20 07:05AM  
Mar-02-20 07:00AM  
Feb-27-20 07:20AM  
Feb-24-20 04:01PM  
Feb-23-20 06:38PM  
Feb-05-20 07:00AM  
Feb-03-20 07:00AM  
Jan-13-20 07:00AM  
Jan-08-20 07:00AM  
Jan-02-20 04:01PM  
Dec-19-19 06:47AM  
Dec-18-19 07:00AM  
Dec-13-19 11:03AM  
Dec-04-19 07:00AM  
Nov-22-19 12:19PM  
Nov-21-19 07:00AM  
Nov-11-19 07:00AM  
Nov-09-19 07:02PM  
Nov-06-19 06:35PM  
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zaderej Karen L.CEODec 27Option Exercise0.004,4000927,429Dec 29 04:33 PM
Scopelianos AngeloChief R&D OfficerDec 27Option Exercise0.001,150011,270Dec 29 04:31 PM
MARTINEZ MARIA D.Chief Human Resources OfficerDec 27Option Exercise0.001,15006,017Dec 29 04:30 PM
MARIANI PETER JEVP & Chief Financial OfficerDec 27Option Exercise0.002,625024,794Dec 29 04:28 PM
Friedman Mark LouisVP Regulatory Affairs & PolicyDec 27Option Exercise0.001,150017,738Dec 29 04:23 PM
Donovan Michael PatrickVP OperationsDec 27Option Exercise0.001,150042,269Dec 29 04:21 PM
DeVinney Erick WayneVP Peripheral Nerve ScienceDec 27Option Exercise0.00750087,436Dec 29 04:17 PM
Billet IsabelleChief Strategy and BD OfficerDec 27Option Exercise0.001,150014,510Dec 29 04:15 PM
MARIANI PETER JEVP & Chief Financial OfficerDec 20Option Exercise0.001,900022,926Dec 22 04:07 PM
Zaderej Karen L.CEODec 20Option Exercise0.003,1250924,272Dec 22 04:09 PM
Friedman Mark LouisVP Regulatory Affairs & PolicyDec 20Option Exercise0.00375016,683Dec 22 04:06 PM
Donovan Michael PatrickVP OperationsDec 20Option Exercise0.00375041,214Dec 22 04:04 PM
DeVinney Erick WayneVP Peripheral Nerve ScienceDec 20Option Exercise0.00575086,830Dec 22 04:03 PM
DeVinney Erick WayneVP Peripheral Nerve ScienceDec 15Option Exercise3.6710,00036,70090,426Dec 17 04:02 PM
Zaderej Karen L.CEONov 24Option Exercise8.9552,375468,756921,147Nov 29 04:09 PM
Zaderej Karen L.CEOAug 13Option Exercise3.6746,500170,655868,772Aug 16 04:10 PM
Zaderej Karen L.CEOAug 12Option Exercise5.098,25442,013822,272Aug 16 04:10 PM
Zaderej Karen L.CEOAug 10Option Exercise5.0975,000381,750855,018Aug 10 04:52 PM
Zaderej Karen L.CEOAug 06Sale18.4741,000757,194814,018Aug 10 04:52 PM
Donovan Michael PatrickVP OperationsJul 21Sale20.041,93538,77740,839Jul 23 04:06 PM
Freitag Gregory GeneDirectorJun 17Option Exercise19.179,250177,323364,556Jun 21 04:17 PM
MARTINEZ MARIA D.Chief Human Resources OfficerJun 04Sale18.862,65250,0172,932Jun 08 04:25 PM
Gold Mark StephenDirectorJun 01Option Exercise0.006,1730302,439Jun 03 05:15 PM
Wendell Amy McBrideDirectorJun 01Option Exercise0.006,173032,097Jun 03 05:14 PM
NEELS GUIDO JDirectorJun 01Option Exercise0.006,173048,764Jun 03 05:12 PM
Blackford Quentin S.DirectorJun 01Option Exercise0.006,173024,299Jun 03 05:13 PM
Levine Alan MDirectorJun 01Option Exercise0.006,17308,764Jun 03 05:11 PM
Freitag Gregory GeneDirectorMay 26Option Exercise6.72102,954692,001331,306May 28 04:05 PM
NEELS GUIDO JDirectorMay 19Option Exercise4.2840,000171,35042,591May 21 04:21 PM
DeVinney Erick WayneVP of Clin. & Trans. SciencesApr 28Option Exercise2.8610,00028,60078,082Apr 30 04:10 PM
Zaderej Karen L.CEOApr 16Option Exercise5.09100,000509,000765,912Apr 20 04:09 PM
Zaderej Karen L.CEOMar 25Option Exercise3.6734,500126,615665,912Mar 29 04:17 PM
Freitag Gregory GeneDirectorFeb 25Sale22.0624,000529,440228,352Mar 01 04:08 PM
Donovan Michael PatrickVP OperationsFeb 18Sale19.151,80834,62340,839Feb 19 04:12 PM
Donovan Michael PatrickVP OperationsFeb 05Option Exercise5.1420,000102,80046,029Feb 09 07:12 PM